Detailed characterization of the modulation of lead metabolism in bone is necessary to understand the role of skeletal lead in the expression of clinical and biochemical effects of lead. The metabolism of lead in osseous tissue is also important clinically because it is the major site of chelation by therapeutic agents, such as CaNazEDTA and d-penicillamine. Experiments were conducted to characterize the steady-state kinetic distribution and behavior of 210~b and to identify the biological structures or functions associated with the kinetic pools. Bone cells, derived from mouse calvaria, were enriched for osteoclasts by a sequential collagenase digestion and maintained in primary culture for 1 week. Cultures were labeled with 210~b as 5 !JM lead acetate for 20 hr and the kinetic parameters were obtained by analysis of 21°pb washout curves. Cellular metabolism was defined by three kinetic pools of intracellular lead containing %lo% (Sl), "15% (S2) and %75% (S3) of total cellular lead (1.7-2.2 nmoljmg cell protein). The halftimes for isotopic exchange were 1, 40 and 1000 minutes, respectively. Less than one half of S1 was labile to chelation by EGTA and thus defined as extracellular. KCN, DNP and DBcAMP decreased S3, whereas increasing medium Po4 to 4 mM increased S3, thereby suggesting that S3 includes mitochondria1 'lOpb.
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These data indicate that lead is readily mobilized from osteoclastic bone cells and, like soft tissues (hepatocytes), the bulk of cellular lead is associated with mitochondria. Infants with polycythemia are known to have reduced cerebral blood flow (CBF). To determine if this flow reduction is associated with abnormalities in cerebral oxygen and carbohydrate metabolism, we studied eight newborn lambs during a control period and at 60, 180 and 300 minutes after exchange transfusion (ET) with newborn packed red blood cells. 
We conclude that in the neonatal lamb a polycythemia-induced fall in G and CBF effected a significant depression in G delivery and QG. Hereditary tyrosinemia i s an autosomal recessive disease r es u l t i n g i n hepatorenal dysfunction. The renal manifestations o f the disease i n c l u d e renal t u b u l a r acidosis o f t h e proximal v a r ie t y , aminoaciduria, glycosuria and phosphaturia comprising t h e e n t i t y known as t h e Fanconi syndrome. I n d i v i d u a l s w i t h t h i s d i sease excrete l a r g e amounts o f succinylacetone, a c a t a b o l i c endproduct o f tyrosine, i n t h e i r u r i n e . W e have examined i n v i t r o t h e renal t u b u l a r t r a n s p o r t i n t e r a c t i o n s o f SA w i t h t h e D-glucose t r a n s p o r t analogue, AMG i n r a t renal tubules.
AMG uptake by the r a t renal t u b u l e was markedly i n h i b i t e d by 4 m M SA i n v i t r o . The e f f e c t was immediate i n onset, was p r im a r i l y on substrate e n t r y and was r e f l e c t e d by a 50% decrease i n oxygen consumption. On the o t h e r hand, 4 m M SA caused no f i n e s t r u c t u r a l a l t e r a t i o n s i n mitochondria o r brush border membrane. The i n h i b i t i o n o f AMG uptake could be reversed by removing SA from t h e medium, and was non-competitive i n nature. These data are c o n s i s t e n t w i t h t h e hypothesis t h a t SA o r succinylacetoacetate from which i t i s derived may be c a u s a l l y r e l a t e d t o the Fanconi syndrome i n h e r e d i t a r y tyrosinemia. I 
t i s concluded t h a t t h e use o f SA f o r i n v i t r o study o f renal t u b u l a r t r a n s p o r t dysfunction may provide a p h y s i o l o g i c model f o r i nv e s t i g a t i o n o f t h e human Fanconi syndrome.

NATURAL HISTORY AND DIAGNOSTIC DELAY IN PARTIAL ORIIITHINE TRANSCARBAMYLASE DEFICIENCY (POTCD).
' 252 Peter C. Rowe The natural history of 13 females with POTCD was reviewed.
Patients presented as early as 1 week or as late as 6 years.
The most common symptoms before diagnosis were non-specific: extreme irritability (100X), recurrent vomiting and lethargy (loo%), protein avoidance (92%), ataxia (75%), stage I1 coma ( 4 6 % ) , failure to thrive (46%), and seizures (31%). The median delay between the onset of major symptoms (vomiting and lethargy; seizures; coma) and diagnosis was 16 mos. (range 1-142 mos.).
In 38% there was a positive family history. Plasma levels at diagnosis were: NH 53-520 uM (NL< 35) ; AST (median) 83 U/L; ALT (median) 337 u~L ; urea, 3-13 mgldl; citrulline, trace-21 uM (NL: 10-34).
Liver OTC activity was 2-55% of normal. Five patients had I.Q. scores < 70 at the time of diagnosis. For those with 2 1 episode of stage I1 coma, the mean I.Q. was 52. Common mis-diagnoses were gastroenteritis, colic, Reye's syndrome, psychogenic cyclical vomiting, and poor maternal-child interactions. Clues to early diagnosis are (1) a positive family history, (2) protein avoidance, (3) recurrent symptoms, (4) response to withdrawal of protein, and (5) onset at the time of weaning from breast milk. Early diagnosis allows prompt recognition and treatment of hyperammonemic episodes, thus reducing the risk of subsequent neurological impairment.
TREATMENT OF EARLY NEONATAL HYPOCALCEMIA. Meir
1253 Salameh & Alan R. Fleischman, Albert ~i n s t e E o l l e g e of Medicine, Division of Neonatology, Bronx, N.Y. Hypocaloemia is a major biochemical abnormality in the first three days of life. This study was designed to define the optimal approach to treatment of this disorder. 12 neonates with ionized calcium levels (Cai) <3.0 mg/dl in the first 2 days of life were randomized into two treatment regimens: 7 received bolus infusion over 20 minutes of 125 mg/kg/dose of calcium gluconate Q6H (500 mg/kg/d) and 5 received constant infusion over 24 hours of 500 mg/kg/d. Cai was measured serially over the subsequent 48 hours of treatment (mean f SE) : Hrs Both methods were able to maintain Cai >3.0 mg/dl. The bolus method resulted in large non-physiologic oscillations in Cai while the constant infusion method required several hours to reach physiologic levels but then maintained a constant Cai.
We conclude that constant infusion is a more physiologic approach to the treatment of early neonatal hypocalcemia and are presently studying the use of an initial bolus followed by a constant infusion in order to optimize treatment of hypocalcemia. This increase is not due to elevation in the hepatic subcomponent of "earlylabeled" bilirubin (ELB) formation as measured by 4~-4 -~-aminolevulinic (J Pediatr Gastroenterol Nutr 3:790, 1984) . This study examines total ELB formation in rats 3 days after complete common bile duct ligation. VeCO was measured preoperatively and on the third day after creation of complete biliary obstruction. ' l & e rate of ELB formation was measured by re very of exhaled CO following intraperitoneal injection of "C-2-glycine (20 $i/100gm) on the third postoperative day. Preoperatively, there was no significant difference in the VeCO between control and experimental rats. On the third postoperative day, the VeCO of control rats had returned to baseline from an elevated rate, due to the surgery, while the VeCO of experimental rats was increased by 31% (paired t-test, p < 0.02).
Total fractional recovery of injected label over a-36 hr collection period was similar for co trol (8.5t0.7 x 10 , n=8) and experimental (8.2'0.2 + l o -' , n=7) rats. Based on these data, we conclude that the rise in TBF in this obstructive model is not due to ELB formation. The results further suggest that increased red cell destruction occurs rapidly after short-term biliary obstruction, and may cause the increased TBF, contributing to the pathogenesis of obstructive jaundice.
